NCT01007864 (PIVICOG-PD) is a Phase 3 clinical trial of piribedil in Idiopathic Parkinson's Disease, sponsored by Desitin Arzneimittel GmbH.

Who is sponsoring NCT01007864?

NCT01007864 is sponsored by Desitin Arzneimittel GmbH.

What drugs are being tested in NCT01007864?

Interventions in NCT01007864: piribedil, pramipexole or ropinirole.

What condition does NCT01007864 study?

NCT01007864 studies Idiopathic Parkinson's Disease.

Is NCT01007864 still recruiting?

NCT01007864 is currently completed. Last updated 23 May 2012.

Last reviewed 2012-05-23 · How we verify

NCT01007864: PIVICOG-PD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine Agonists

Completed Phase 3 Last updated 23 May 2012

What this trial tests

Phase 3 trial testing piribedil in Idiopathic Parkinson's Disease in 80 participants. Completed in 1 December 2011.

Timeline

1 January 2010

Primary endpoint
1 December 2011

1 December 2011

Quick facts

Lead sponsor	Desitin Arzneimittel GmbH
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	80
Start date	1 January 2010
Primary completion	1 December 2011
Estimated completion	1 December 2011
Sites	12 locations across Germany

Drugs / interventions tested

piribedil (PIRIBEDIL) — full drug profile →
pramipexole or ropinirole — full drug profile →

Conditions studied

Idiopathic Parkinson's Disease — all drugs for Idiopathic Parkinson's Disease →

Sponsor

Desitin Arzneimittel GmbH — full company profile →

Who can join

Adults 35 to 80, any sex, with Idiopathic Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The primary efficacy variable will be the 'median reaction time during the second 15 minutes (minutes 16-30)' of the subtest 'vigilance', visual test condition 'moving bar', of the Test battery for Attention Performances (TAP) at end of treatment.
Time frame: Baseline and End of Treatment

Sponsor's own description

The purpose of this clinical trial is to investigate the effects of the non-ergot dopamine agonist piribedil on vigilance and cognitive performances in patients with Parkinson's disease in comparison with other oral non-ergot dopamine agonists. It should be tested whether piribedil is superior to continued pramipexole or ropinirole treatment regarding improvement of reduced vigilance and cognitive performance in patients with Parkinson's disease.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Treatment for mild cognitive impairment: systematic review.
Cooper C, Li R, Lyketsos C, Livingston G. · · 2013 · cited 155× · PMID 24085737 · DOI 10.1192/bjp.bp.113.127811
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.
Wong TS, Li G, Li S, Gao W, et al · · 2023 · cited 113× · PMID 37137892 · DOI 10.1038/s41392-023-01427-2
Cognitive Impairment in Parkinson's Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches.
Degirmenci Y, Angelopoulou E, Georgakopoulou VE, Bougea A. · · 2023 · cited 32× · PMID 37893474 · DOI 10.3390/medicina59101756
Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.
Guo X, Liu H, Song YJ, Wang JH, et al · · 2026 · cited 2× · PMID 41583906 · DOI 10.1002/mco2.70497

Verify or expand the search:

Other Desitin Arzneimittel GmbH trials

Trials by the same sponsor.

NCT07393022 — Bioequivalence Study of Levetiracetam 1500 mg Coated Granules in Healthy, Male Subjects · Phase 1 · completed
NCT06214130 — Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets · Phase 1 · completed
NCT06211283 — Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects. · Phase 1 · completed
NCT06199791 — Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditions · Phase 1 · completed
NCT05236842 — Efficacy, Safety and Tolerability of Sulthiame in Patients With Obstructive Sleep Apnea (OSA) · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01007864 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Desitin Arzneimittel GmbH
Last refreshed: 23 May 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01007864.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing